![Charles Link](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles Link
Fondateur chez
Syncromune, Inc.
Profil
Charles J.
Link was the founder of NewLink Genetics Corp.
(1999), serving as Chairman, Chief Executive & Scientific Officer from 2003 to 2019; Central Iowa Hospital Corp.
(1995), serving as Director from 1995 to 2003; and Syncromune, Inc. (2020), serving as Executive Chairman.
Current jobs include Director at NovaScan, Inc. (2020 - present), Director at ImmunSYS, Inc. (present), and Director at Viewpoint Molecular Targeting, Inc. (2021 - present).
Former jobs include Chairman & Chief Executive Officer at BioProtection Systems Corp.
(2005 - 2009), Independent Director at QSAM Biosciences, Inc. (2021 - 2024), and Chief Executive & Scientific Officer at Lumos Pharma, Inc. Education includes a doctorate from Stanford University School of Medicine.
Postes actifs de Charles Link
| Sociétés | Poste | Début |
|---|---|---|
ImmunSYS, Inc.
 ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology Manufactures cancer immunotherapy products | Directeur/Membre du Conseil | - |
NovaScan, Inc.
 NovaScan, Inc. Medical SpecialtiesHealth Technology Manufactures cancer detection instrument | Directeur/Membre du Conseil | 01/01/2020 |
Viewpoint Molecular Targeting, Inc.
 Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Directeur/Membre du Conseil | 18/05/2021 |
Syncromune, Inc.
 Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops intratumoral immunotherapy platform for treating metastatic solid tumors | Fondateur | 01/01/2020 |
Anciens postes connus de Charles Link
| Sociétés | Poste | Fin |
|---|---|---|
QSAM Biosciences, Inc.
 QSAM Biosciences, Inc. Chemicals: AgriculturalProcess Industries Manufactures compost | Directeur/Membre du Conseil | 02/05/2024 |
| LUMOS PHARMA, INC. | Directeur Général | 03/08/2019 |
| LUMOS PHARMA, INC. | Directeur Général | 03/08/2019 |
BioProtection Systems Corp.
 BioProtection Systems Corp. BiotechnologyHealth Technology Manufacturers biological products | Président | 01/01/2009 |
Central Iowa Hospital Corp. | Fondateur | 01/01/2003 |
Formation de Charles Link
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
22
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops, and commercializes novel immunotherapeutic products for treatment of cancer | Health Technology |
BioProtection Systems Corp.
BioProtection Systems Corp. BiotechnologyHealth Technology Manufacturers biological products | Health Technology |
Central Iowa Hospital Corp. | |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
QSAM Biosciences, Inc.
QSAM Biosciences, Inc. Chemicals: AgriculturalProcess Industries Manufactures compost | Process Industries |
NovaScan, Inc.
NovaScan, Inc. Medical SpecialtiesHealth Technology Manufactures cancer detection instrument | Health Technology |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology Manufactures cancer immunotherapy products | Health Technology |
Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
Lumos Pharma, Inc.
 Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases | Health Technology |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops intratumoral immunotherapy platform for treating metastatic solid tumors | Health Technology |
